Editpep
Organisation
Grants and prizes
SBIR, Sbir phase i: development of brain-penetrant non-viral genome-editing therapies for central nervous system disorders, 2604362, US$305k, 2026–2027, 1 Jul 2026
Sources: usaspending.gov
Organisation
SBIR, Sbir phase i: development of brain-penetrant non-viral genome-editing therapies for central nervous system disorders, 2604362, US$305k, 2026–2027, 1 Jul 2026
Sources: usaspending.gov